NCT05523440 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05523440
Title	Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
Recruitment	Terminated
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	University of Oklahoma
Indications	ovarian cancer endometrial cancer
Therapies	Bevacizumab + Niraparib Niraparib
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 2 of 2 entries

Facility	Status	City	State	Zip	Country	Details
University of Oklahoma Health Sciences Center, Stephenson Cancer Center		Oklahoma City	Oklahoma	73104	United States	Details
University of Virginia Comprehensive Cancer Center		Charlottesville	Virginia	22903	United States	Details

Showing 1 to 2 of 2 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT05523440Clinical Trial Detail